← Research library

Langopept Phase II placebo-controlled COPD trial registration

Planned study · 2023

Registered population or design
200 planned participants with moderate-to-severe chronic obstructive pulmonary disease (COPD). Actual enrollment and arm sizes are unavailable.
Results availability
PeptidPRO’s double-blind COPD trial lists 200 planned participants. Clinomir marks the study completed. Actual enrollment, doses administered and results remain unavailable.

Reported findings and study design

The patent gives no measured outcomes

Multicenter, double-blind, randomized, parallel-group placebo-controlled design. ClinLine lists investigators T. I. Ishina, V. V. Popov and N. D. Krasnopeeva.

Dose, route and schedule

The registry lists a 5 mg lyophilized formulation for intramuscular injection and a placebo control. It does not give the per-visit dose, frequency or treatment duration.

Protocol source ↗ · ClinLine trial entry and Clinomir sponsor listing for PeptidPRO.

Results · ClinLine trial entry and Clinomir sponsor listing for PeptidPRO.
MeasureResultComparison, timing and statistics
Planned enrollment200 participants

Source for these results ↗ · Reviewed 2026-11-15

Study limitations and source details

Study limitations

  • The registry target was 200. Clinomir gives an administrative completion status without participant flow, study endpoint data, or adverse-event tables.

Source details

Trial registry reproduction

ClinLine trial entry and Clinomir sponsor listing for PeptidPRO.

Sources checked

Citation

Trial protocol / registrationFull text available

PeptidPRO. Langopept Phase II placebo-controlled COPD trial registration Russian clinical-trial registry record, authorization 262, 5 May 2023. Protocol LNG-11-2022.

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards